2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

2019 Annals of the Rheumatic Diseases 1,890 citations

Abstract

Our objective was to update the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic literature review (01/2007–12/2017), followed by modified Delphi method, to form questions, elicit expert opinions and reach consensus. Treatment in SLE aims at remission or low disease activity and prevention of flares. Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. During chronic maintenance treatment, glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent) and, when possible, withdrawn. Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can expedite the tapering/discontinuation of GC. In persistently active or flaring extrarenal disease, add-on belimumab should be considered; rituximab (RTX) may be considered in organ-threatening, refractory disease. Updated specific recommendations are also provided for cutaneous, neuropsychiatric, haematological and renal disease. Patients with SLE should be assessed for their antiphospholipid antibody status, infectious and cardiovascular diseases risk profile and preventative strategies be tailored accordingly. The updated recommendations provide physicians and patients with updated consensus guidance on the management of SLE, combining evidence-base and expert-opinion.

Keywords

MedicineBelimumabHydroxychloroquineRituximabAzathioprineIntensive care medicineAntiphospholipid syndromeSystemic lupus erythematosusExpert opinionPrednisoneDiseaseTocilizumabImmunologyInternal medicineInfectious disease (medical specialty)AntibodyB-cell activating factor

MeSH Terms

Biological ProductsComorbidityDisease ManagementEvidence-Based MedicineGlucocorticoidsHumansHydroxychloroquineImmunosuppressive AgentsLupus ErythematosusSystemicSeverity of Illness Index

Affiliated Institutions

Related Publications

<scp>I</scp>nternational <scp>S</scp>ociety of <scp>N</scp>europathology‐<scp>H</scp>aarlem <scp>C</scp>onsensus <scp>G</scp>uidelines for <scp>N</scp>ervous <scp>S</scp>ystem <scp>T</scp>umor <scp>C</scp>lassification and <scp>G</scp>rading

Abstract Major discoveries in the biology of nervous system tumors have raised the question of how non‐histological data such as molecular information can be incorporated into t...

2014 Brain Pathology 559 citations

Publication Info

Year
2019
Type
article
Volume
78
Issue
6
Pages
736-745
Citations
1890
Access
Closed

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1890
OpenAlex
82
Influential
1559
CrossRef

Cite This

Antonis Fanouriakis, Myrto Kostopoulou, Alessia Alunno et al. (2019). 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases , 78 (6) , 736-745. https://doi.org/10.1136/annrheumdis-2019-215089

Identifiers

DOI
10.1136/annrheumdis-2019-215089
PMID
30926722

Data Quality

Data completeness: 90%